Panbela announces acceptance of abstract for poster presentation at american society of clinical oncology gastrointestinal cancers symposium

Minneapolis, nov. 18, 2021 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for sbp-101, a proprietary polyamine analogue, has been accepted for poster presentation at the american society of clinical oncology (asco) gastrointestinal cancers symposium, which will be held january 20-22, 2022.
PBLA Ratings Summary
PBLA Quant Ranking